Journal of the National Comprehensive Cancer Network : JNCCN This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Outcomes of a Dietary Intervention to Reduce Bladder Cancer Recurrence and Progression in Survivors of Non-Muscle-Invasive Bladder Cancer
CONCLUSIONS: Our dietary intervention is the first to significantly increase Cruciferae intake and urinary ITC levels in NMIBC survivors, demonstrating an increase in ITC to levels that significantly decrease risk of disease-specific survival. A future randomized controlled trial testing POW-R Health on bladder cancer recurrence and progression is warranted. If proven to improve bladder cancer outcomes, our intervention has the potential to be a noninvasive, cost-effective, easily accessible way for NBMIC survivors to improve their bladder cancer prognosis.PMID:38408431 | DOI:10.6004/jnccn.2023.7086 (Source: Journal of the...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 26, 2024 Category: Cancer & Oncology Authors: Karen H Kim Yeary Han Yu Margaret Gates Kuliszewski Qiang Li Susan E McCann Rachel Pratt Frances G Saad-Harfouche Zinian Wang Nikia Clark Chong Wang Elizabeth DiCarlo Li Tang Source Type: research

Value of Size and Malignant Features of Lateral Lymph Nodes in Risk Stratification at Lateral Local Recurrence of Rectal Cancer: A National Cohort Study
CONCLUSIONS: The presence of multiple enlarged LLNs (≥7.0 mm), as well as multiple malignant features in an enlarged node contribute to the risk of developing an LLR. These radiologic features can be used for clinical decision-making regarding the potential benefit of LLN dissection.PMID:38394768 | DOI:10.6004/jnccn.2023.7081 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 23, 2024 Category: Cancer & Oncology Authors: Eline G M van Geffen Tania C Sluckin Sanne-Marije J A Hazen Karin Horsthuis Regina G H Beets-Tan Susan van Dieren Corrie A M Marijnen Pieter J Tanis Miranda Kusters Source Type: research

Guest Editorial: Reflections of a New Chief Executive Officer
J Natl Compr Canc Netw. 2024 Feb;22(1):1-2. doi: 10.6004/jnccn.2024.0009.NO ABSTRACTPMID:38394769 | DOI:10.6004/jnccn.2024.0009 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 23, 2024 Category: Cancer & Oncology Authors: Crystal S Denlinger Source Type: research

Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
J Natl Compr Canc Netw. 2024 Feb;22(1):43-69. doi: 10.6004/jnccn.2024.0007.ABSTRACTChronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase-CML. The primary goal of TKI therapy in patients with chronic phase-CML is to prevent...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 23, 2024 Category: Cancer & Oncology Authors: Neil P Shah Ravi Bhatia Jessica K Altman Maria Amaya Kebede H Begna Ellin Berman Onyee Chan Joan Clements Robert H Collins Peter T Curtin Daniel J DeAngelo Michael Drazer Lori Maness Leland Metheny Sanjay Mohan Joseph O Moore Vivian Oehler Keith Pratz Isk Source Type: research

Disparities in Survival and NCCN Guideline-Concordant Care in Patients With Extremity Soft Tissue Sarcoma
CONCLUSIONS: Patients from lower nSES areas were less likely to receive NCCN Guideline-recommended RT for their ESTS and had worse cancer-specific survival. Efforts to better define and resolve disparities in the treatment and survival of patients with ESTS are warranted.PMID:38394772 | DOI:10.6004/jnccn.2023.7075 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 23, 2024 Category: Cancer & Oncology Authors: Hayley M Dunlop Bence Bende Samantha M Ruff Alex Kim James L Fisher Valerie P Grignol Carlo M Contreras Samilia Obeng-Gyasi David J Konieczkowski Timothy M Pawlik Raphael E Pollock Joal D Beane Source Type: research

Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors
J Natl Compr Canc Netw. 2024 Feb;22(1):e237116. doi: 10.6004/jnccn.2023.7116.ABSTRACTOver the past several years, advances in research, treatment, and market dynamics have impacted treatment strategies in chronic myeloid leukemia in chronic phase (CML-CP). They include the broader availability of cost-effective generic imatinib, and soon other generic second-generation tyrosine kinase inhibitors (TKIs). Access to affordable generics means that all patients with CML-CP should have access to safe and highly effective lifelong therapies. When overall survival is the treatment endpoint, imatinib provides a good treatment value...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 23, 2024 Category: Cancer & Oncology Authors: Fadi G Haddad Hagop Kantarjian Source Type: research

Beyond BCR::ABL1-The Role of Genomic Analyses in the Management of CML
J Natl Compr Canc Netw. 2024 Feb;22(1):e237335. doi: 10.6004/jnccn.2023.7335.ABSTRACTChronic myeloid leukemia (CML) is a model of genomically based diagnosis and management where BCR::ABL1 is successfully targeted by tyrosine kinase inhibitor (TKI) therapy in most patients. The dynamics of BCR::ABL1 transcript decline during therapy is a dependable biomarker of response, relapse, and drug resistance. Missense mutations acquired within the BCR::ABL1 kinase domain that disrupt TKI binding can evolve during therapy and are frequently detected in patients for whom TKI treatment fails. Importantly, specific BCR::ABL1 missense m...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 23, 2024 Category: Cancer & Oncology Authors: Susan Branford Adelina Fernandes NurHezrin Shahrin Muneeza Maqsood Naranie Shanmuganathan Carol Wadham Source Type: research

Patient-Centered Decision-Making in Metastatic Breast Cancer Care Delivery: A Call to Action
J Natl Compr Canc Netw. 2024 Feb;22(1):e237113. doi: 10.6004/jnccn.2023.7113.NO ABSTRACTPMID:38394778 | DOI:10.6004/jnccn.2023.7113 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 23, 2024 Category: Cancer & Oncology Authors: Gabrielle B Rocque Manali I Patel Lauren P Wallner Stacy C Bailey Rebekkah Schear Christine M Gunn Jamil Rivers Rozanne Wilson Emily C Freeman Trudy L Buckingham Suepattra G May Arif H Kamal Source Type: research

An Infant-Type Hemispheric Glioma With SOX5::ALK: A Novel Fusion
In conclusion, we identified a case of congenital IHG with a novel SOX5::ALK fusion that had progressed after chemotherapy and showed partial response and clinical benefit after treatment with the CNS-active ALK inhibitor lorlatinib.PMID:38394779 | DOI:10.6004/jnccn.2023.7102 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 23, 2024 Category: Cancer & Oncology Authors: Chia Chin Tsai Man-Hsu Huang Chia-Lang Fang Kevin Li-Chun Hsieh Tsung-Han Hsieh Wan-Ling Ho Hsi Chang Min-Lan Tsai Yu-Chien Kao James S Miser Tai-Tong Wong Min-Yu Su Yen-Lin Liu Source Type: research

NCCN Guidelines ® Insights: Kidney Cancer, Version 2.2024
J Natl Compr Canc Netw. 2024 Feb;22(1):4-16. doi: 10.6004/jnccn.2024.0008.ABSTRACTThe NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on the systemic therapy options for patients with advanced RCC and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Kidney Cancer.PMID:38394781 | DOI:10.6004/jnccn.2024.0008 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 23, 2024 Category: Cancer & Oncology Authors: Robert J Motzer Eric Jonasch Neeraj Agarwal Ajjai Alva Hilary Bagshaw Michael Baine Kathryn Beckermann Maria I Carlo Toni K Choueiri Brian A Costello Ithaar H Derweesh Arpita Desai Yasser Ged Saby George John L Gore Andrew Gunn Naomi Haas Michael Johnson Source Type: research

Association Between Alcohol Use Disorder and Hospital Readmission Rates and Outcomes in Cancer Survivors: A Population Cohort Study
CONCLUSIONS: This population-based cohort study of cancer survivors in the United States found that AUD is associated with higher 90- and 180-day readmission rates and higher related health care costs after 90 days of follow-up. Hospitalized cancer survivors with AUD may benefit from addiction treatment and discharge planning that addresses their co-occurring AUD.PMID:38394782 | DOI:10.6004/jnccn.2023.7076 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 23, 2024 Category: Cancer & Oncology Authors: Jyun-Heng Lai Sola Han Chanhyun Park Anton L V Avance ña Source Type: research

Group Coping Intervention in Patients With Chronic Graft-Versus-Host Disease: A Pilot Randomized Clinical Trial
CONCLUSIONS: Participation in a multidisciplinary group intervention study was feasible for patients with chronic GVHD, with promising signals for improving QoL and mood. A full-scale efficacy trial is needed to confirm effects on patient-reported outcomes.PMID:38394783 | DOI:10.6004/jnccn.2023.7080 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 23, 2024 Category: Cancer & Oncology Authors: Ashley M Nelson Daniel Yang Annemarie D Jagielo Jennifer D'Alotto Cathleen Poliquin Dustin J Rabideau Katherine G Cronin Richard A Newcomb Yi-Bin Chen Zachariah DeFilipp Joseph A Greer Areej El-Jawahri Lara Traeger Source Type: research